News

Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus ...
In the pivotal CREST clinical trial, sasanlimab in combination with Bacillus Calmette-Guérin met the primary endpoint of ...
Imagine what we could do if we could take that time and replace it with a single login to a centralized, one stop shop system ...